ANXA2 and breast cancer: We found that high serum exo-AnxA2 levels (n = 54) were associated with worse DFS (hazard ratio 7.934; 95% CI = 1.778–35.398; log-rank P = 0.0301) in breast cancer patients (n = 53; Fig. 3c).